article thumbnail

HP&M Counsel John Claud Provides Testimony to House Subcommittee on FDA Foreign Inspections

FDA Law Blog: Biosimilars

Mr. Claud was joined in his testimony by Mary Denigan-Macauley , a Director for Health Care at the Government Accountability Office (GAO) and Dinesh Thakur. Mr. Claud closed his testimony echoing that sentiment. Mr. Thakur is a public health advocate and a former executive at Ranbaxy Laboratories in India.

article thumbnail

R&D Partnering Testimonials from Bayer, Oldcastle and Joyn Bio

Translation

The company received proposals from over fifty institutions, including 40 universities and 10 government labs, surfacing licensing candidates from diverse partners. The post R&D Partnering Testimonials from Bayer, Oldcastle and Joyn Bio appeared first on Translation | Halo Blog.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Article FDA Thank You Explainer: What a government shutdown would mean for the FDA (Updated)

Agency IQ

Explainer: What a government shutdown would mean for the FDA (Updated) With Congress again debating the passage of appropriations legislation, the FDA is facing a potential shutdown of operations as of Midnight on March 1. What is a government shut down? If none of the 12 bills are completed, then all government operations shut down.

article thumbnail

Analysis Chemical Thank You Senate hearing on hazardous substance listing for PFAS finds common ground, but disagreements on implementation tactics

Agency IQ

The testimony of witnesses and the Senators themselves largely agreed on the designation, but diverged on questions of liability exemptions. The act establishes a liability scheme to authorize the federal government to clean up contaminated sites in the country and force potentially responsible parties (PRPs) to pay for those cleanup costs.

article thumbnail

GAO Report on Clinical Research Inspections Encourages FDA to Care for its Clinical Inspection Program

FDA Law Blog: Biosimilars

In 2022, the Government Accountability Office reported that FDA needed to improve its foreign inspection program. That report prompted a hearing on Capitol Hill in February of this year where HPM Counsel John Claud offered testimony. But gaps still remain.

article thumbnail

Bayer announces filing of petition to U.S. Supreme Court for review of Hardeman decision

The Pharma Data

Government argued in its amicus filing in the Ninth Circuit. Second, the admission of expert testimony departed from federal standards, enabling plaintiff’s causation witnesses to provide unsupported testimony on the principal issue in the case, Roundup ’s safety profile.

article thumbnail

Does the Drug Shortage White Paper Fall Short?

FDA Law Blog: Biosimilars

What about government factors that cause drug shortages? What the White Paper does not adequately address is whether there are any government-controlled factors that also cause drug shortages. For example, how would HRSP incentives/penalties apply to low-cost, high-volume medical devices (e.g., surgical robots, MRIs)? Section I.C

Drugs 59